Shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Get Free Report) have been assigned an average rating of “Moderate Buy” ...

Cantor Fitzgerald began coverage on shares of Summit Therapeutics (NASDAQ:SMMT – Free Report) in a research report sent to investors on Friday, Marketbeat Ratings reports. The brokerage issued an ...

PD-1, PD-L1, and VEGF inhibitors have been approved for over 50 indications in addition to NSCLC. Summit CEO Maky Zanganeh ...

Summit Therapeutics (NASDAQ: SMMT) has been one of the hottest stocks to own over the past 12 months, with its valuation ...

Fintel reports that on March 21, 2025, Cantor Fitzgerald initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Summit Therapeutics (SMMT – Research Report) received a Buy rating and price target from Cantor Fitzgerald analyst Eric Schmidt FCA today.

Cantor Fitzgerald initiated coverage of Summit Therapeutics (SMMT) with an Overweight rating. The firm views shares as 67% undervalued, the ...

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Robert LaCaze has joined ...

Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal ...

Summit Therapeutics (NASDAQ: SMMT) has been one of the hottest stocks to own over the past 12 months, with its valuation soaring 300% during that stretch. But things have slowed of late and since ...